MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-12-2026
GBS Total Assets 2011-2026 | GBS
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets GBS
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.25 M | 13.8 M | 10.4 M | 12.4 M | 21.9 M | 2.48 M | 2.33 M | 2.5 M | 667 K | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 21.9 M | 667 K | 8.28 M |
Quarterly Total Assets GBS
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 17.7 M | 10 M | 8.25 M | 9.58 M | 8.68 M | 11.7 M | 13.8 M | 17 M | 8.83 M | 8.7 M | 10.4 M | 10.7 M | 18 M | - | 12.4 M | 14.4 M | 15.2 M | 19.1 M | 21.9 M | 21.9 M | 20 M | 2.48 M | 2.48 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 21.9 M | 2.48 M | 12.9 M |
Total Assets of other stocks in the Medical devices industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aziyo Biologics
AZYO
|
43.4 M | - | 1.37 % | $ 20.5 M |  USA |
 |
Bruker Corporation
BRKR
|
5.81 B | $ 38.96 | -0.79 % | $ 5.8 K | USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
224 M | - | - | $ 1.77 B | USA |
 |
Conformis
CFMS
|
94 M | - | - | $ 16.4 M | USA |
 |
Cardiovascular Systems
CSII
|
323 M | - | 0.15 % | $ 844 M | USA |
 |
Cutera
CUTR
|
346 M | - | -10.19 % | $ 1.99 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
10.6 M | - | -5.86 % | $ 30.6 M | USA |
 |
Acutus Medical
AFIB
|
54 M | - | -26.83 % | $ 2.62 M | USA |
 |
Dynatronics Corporation
DYNT
|
15.4 M | - | 14.99 % | $ 929 K | USA |
 |
Eargo
EAR
|
132 M | - | - | $ 10.2 M | USA |
 |
Cognyte Software Ltd.
CGNT
|
498 M | $ 8.14 | 4.09 % | $ 584 M |  Israel |
 |
Allied Healthcare Products
AHPI
|
19.7 M | - | 3.58 % | $ 2.21 M | USA |
 |
Second Sight Medical Products
EYES
|
41.6 M | - | -0.97 % | $ 54.4 M | USA |
 |
EDAP TMS S.A.
EDAP
|
86.1 M | $ 4.14 | 3.82 % | $ 154 M |  France |
 |
Electromed
ELMD
|
53.8 M | $ 24.4 | 1.73 % | $ 206 M | USA |
 |
AdaptHealth Corp.
AHCO
|
4.32 B | $ 9.7 | 3.19 % | $ 1.31 B | USA |
 |
FONAR Corporation
FONR
|
199 M | $ 18.54 | 0.19 % | $ 122 M | USA |
 |
Apollo Endosurgery
APEN
|
110 M | - | - | $ 475 M | USA |
 |
CONMED Corporation
CNMD
|
2.33 B | $ 42.97 | -0.8 % | $ 1.33 B | USA |
 |
CryoLife, Inc.
CRY
|
789 M | - | -4.14 % | $ 702 M | USA |
 |
Avinger
AVGR
|
13.8 M | - | -20.74 % | $ 369 K | USA |
 |
AxoGen
AXGN
|
222 M | $ 29.35 | -1.63 % | $ 1.35 B | USA |
 |
Apyx Medical Corporation
APYX
|
79.2 M | $ 3.3 | 3.94 % | $ 114 M | USA |
 |
Axonics Modulation Technologies
AXNX
|
659 M | - | - | $ 3.31 B | USA |
 |
InMode Ltd.
INMD
|
766 M | $ 13.53 | -0.51 % | $ 874 M | Israel |
 |
IRadimed Corporation
IRMD
|
98.3 M | $ 105.54 | 1.2 % | $ 1.34 B | USA |
 |
Soliton, Inc.
SOLY
|
33.8 M | - | -1.42 % | $ 435 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
10.5 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
64.1 M | - | 0.03 % | $ 1.58 B | Israel |
 |
Accuray Incorporated
ARAY
|
470 M | $ 0.52 | -0.59 % | $ 53.4 M | USA |
 |
Misonix, Inc.
MSON
|
204 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
66.2 M | - | - | $ 111 M |  Canada |
 |
LivaNova PLC
LIVN
|
2.61 B | $ 66.57 | -2.73 % | $ 3.63 B |  Britain |
 |
Medigus Ltd.
MDGS
|
37.5 M | - | 10.28 % | $ 55.5 M | Israel |
 |
Pulmonx Corporation
LUNG
|
163 M | $ 1.45 | -5.23 % | $ 56.7 M | USA |
 |
Cytosorbents Corporation
CTSO
|
47.4 M | $ 0.79 | -1.75 % | $ 43 M | USA |
 |
Medtronic PLC
MDT
|
91.7 B | $ 95.66 | -1.11 % | $ 123 B | USA |
 |
Align Technology
ALGN
|
6.21 B | $ 181.53 | -0.61 % | $ 13.6 B | USA |
 |
Intersect ENT, Inc.
XENT
|
227 M | - | - | $ 955 M | USA |
 |
Inari Medical
NARI
|
504 M | - | - | $ 4.23 B | USA |
 |
Butterfly Network
BFLY
|
256 M | $ 4.01 | 9.1 % | $ 849 M | USA |
 |
BIOLASE
BIOL
|
35.1 M | - | -13.19 % | $ 166 K | USA |
 |
Abbott Laboratories
ABT
|
86.7 B | $ 113.47 | -0.1 % | $ 198 B | USA |
 |
NuVasive
NUVA
|
2.22 B | - | - | $ 2.07 B | USA |
 |
Nevro Corp.
NVRO
|
554 M | - | - | $ 217 M | USA |
 |
BioSig Technologies
BSGM
|
842 K | - | 37.08 % | $ 85.7 M | USA |
 |
Boston Scientific Corporation
BSX
|
43.7 B | $ 72.64 | -1.64 % | $ 108 B | USA |
 |
Orthofix Medical
OFIX
|
851 M | $ 12.93 | -0.77 % | $ 512 M |  Curacao |